Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response captures several on-label safety themes (infection risk, TB screening, live vaccine avoidance, hypersensitivity) but repeatedly makes broad statements about immunosuppressive/biologic co-therapy and immune weakening that are not supported by the provided label excerpts, and it omits several label-specific safety nuances (e.g., IBD monitoring, discontinuation for serious infection resolution, latex risk specifics, and hepatitis B/viral hepatitis cautions).
Category Scores
Accurate Statements
Secukinumab is an IL-17A inhibitor.
Not present in the provided excerpts.
Secukinumab may increase the risk of infections.
5.1 Infections: "COSENTYX may increase the risk of infections." and higher infection rates in trials; postmarketing opportunistic/fatal infections reported.
Live vaccines are generally avoided during secukinumab treatment.
5.7 Immunizations: "Avoid use of live vaccines in patients treated with COSENTYX."
Clinicians usually avoid dual biologic therapy unless there is a specific rationale.
Not supported by the provided label excerpts.
Clinicians commonly screen for tuberculosis in IL-17–targeted biologic treatment pathways.
5.3 Pre-Treatment Evaluation for Tuberculosis: "Evaluate patients for active or latent TB infection prior to initiating treatment"; monitor during/after.
Clinicians typically screen for infections before and during secukinumab therapy.
5.1 Infections: monitor closely if serious infection develops; 5.3 TB evaluation and monitoring for active TB.
Patients on secukinumab should seek medical advice promptly for fever, chills, or feeling acutely unwell.
Supported only in general by instruction to monitor for infections and discontinue/monitor; no explicit symptom list provided in excerpts.
Patients on secukinumab should seek medical advice promptly for persistent cough or shortness of breath.
Only indirectly supported (monitor signs/symptoms of TB/active infection); symptom-specific guidance not present in provided excerpts.
Patients on secukinumab should seek medical advice promptly for burning with urination or other signs of infection.
Only indirectly supported by infection monitoring; symptom-specific guidance not present in provided excerpts.
Patients on secukinumab should seek medical advice promptly for skin infections or worsening redness or pain.
Only indirectly supported by infection monitoring; symptom-specific guidance not present in provided excerpts.
Unsupported Statements
Secukinumab is used for conditions like psoriasis and psoriatic arthritis.
No indication statements were provided in the label excerpts you included, so support cannot be confirmed from the provided material.
Secukinumab can weaken immune responses.
The excerpts mention vaccine immune response alteration (12.2/5.7), but do not explicitly state a general "weaken immune responses" phrasing; support is indirect.
Using secukinumab alongside other immunosuppressive medicines can raise the risk of infections.
The provided label excerpts do not describe co-administration with other immunosuppressives/biologics and associated infection risk.
Combining secukinumab with another biologic used for inflammatory disease typically increases infection risk.
Not supported by the provided label excerpts.
Clinicians usually avoid dual biologic therapy unless there is a specific rationale.
Not supported by the provided label excerpts.
Other biologics targeting inflammatory pathways may increase infection risk when used together with secukinumab.
Not supported by the provided label excerpts.
Co-administration with strong immunosuppressive drugs may increase infection risk with secukinumab.
Not supported by the provided label excerpts.
Secukinumab is commonly used with non-biologic inflammatory disease regimens such as methotrexate or short courses of corticosteroids in real-world practice.
Not supported or mentioned in the provided label excerpts.
When multiple immune-modifying drugs are used together with secukinumab, monitoring for infections is a practical issue.
General monitoring is supported, but the specific linkage to "multiple immune-modifying drugs" is not supported by the provided excerpts.
Food and vitamin interactions are generally not a major issue for secukinumab.
Not supported by the provided label excerpts.
Secukinumab is a monoclonal antibody and is not typically affected by dietary components in the way small-molecule drugs are.
Not supported by the provided label excerpts.
Secukinumab interaction risk may be affected by whether patients have had recent vaccines or are scheduled to receive vaccines.
The label excerpt supports live vaccine avoidance and vaccine immune response alteration, but does not support a broader "interaction risk" framing.
Secukinumab interaction risk may be affected by a history of recurrent or chronic infections.
The label supports exercise caution in patients with chronic/recurrent infections, but does not frame it as an "interaction risk".
Secukinumab interaction risk may be affected by current immunosuppressive therapy, especially other biologics.
Not supported by the provided label excerpts.
Secukinumab dose and schedule may be used to map likely interaction risks.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Combining secukinumab with another biologic used for inflammatory disease typically increases infection risk.
Label Reference
No direct contradiction identified in the provided excerpts; however, the claim is unsupported rather than contradictory.
Important Omissions
IBD-specific safety: monitor for IBD exacerbations; exercise caution in patients with IBD.
Importance:
Moderate
Hepatitis B reactivation and viral hepatitis cautions (e.g., COSENTYX not recommended in active viral hepatitis).
Importance:
Moderate
Clear instruction: if a serious infection develops, monitor closely and discontinue until infection resolves.
Importance:
Moderate
Hypersensitivity discontinuation instructions (immediate discontinuation and appropriate therapy upon serious allergic reaction).
Importance:
Low
Latex sensitivity warning (natural rubber latex in removable cap) for latex-sensitive individuals.
Importance:
Low
Adverse reaction breadth beyond infections (e.g., eczematous eruptions) is not mentioned.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The response includes several broadly framed, co-therapy infection-risk statements that are not supported by the provided label excerpts and omits some label-specific high-relevance safety cautions (IBD exacerbations, hepatitis B/viral hepatitis cautions, and discontinuation guidance for serious infection).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements about infection risk with concurrent immunosuppressants/other biologics and about dietary/vitamin and general "interaction risk" are not supported by the provided COSENTYX label excerpts; the response also omits label-specific warnings (IBD, hepatitis B/viral hepatitis).
Suggested Improvement
Restrict claims to label-supported items from the provided excerpts (infection risk, TB evaluation/monitoring, avoid live vaccines, caution in chronic/recurrent infections) and add omitted label-specific precautions (IBD monitoring, hepatitis B/viral hepatitis cautions, discontinuation/monitoring for serious infection, latex and hypersensitivity instructions).